Hematologic Malignancies

Group Leader:

Prof CHNG Wee Joo

Deputy Director,
CSI Singapore

The Hematologic Malignancies Group within CSI Singapore comprises investigators working on different aspects of leukemia biology to further identify potential therapeutic strategies in a disease where treatment advancement has been lagging. Areas of focus include transcription factors involved in myeloid development, stem cell biology, epigenetics and animal models. The integration of patient materials, suitable model systems, as well as, clinical and industry partnership will facilitate clinical translation. The group continues to grow, harnessing unique expertise and resources, with an aim to conduct world-class, cutting edge research that will push current paradigms so as to improve the outcome of patients with acute leukemia.